Assessment of the Influence of Citrate Concentration on the International Normalized Ratio (INR) Determined with Twelve Reagent-instrument Combinations^[*]

Summary

Citrate concentration is one of the variables that can affect coagulation tests. However, few studies have so far been performed to assess the magnitude of this effect on coagulation tests in general and PT in particular. The aim of this study was to assess the extent of influence of citrate concentration on the PT test with results expressed as INR. Twelve reagent-instrument combinations (systems) were calibrated vs. the Reference Preparation BCT/441 using plasmas collected in either 105 mM or 129 mM citrate from normals and anticoagulated patients (OAT). PTs for plasmas collected in 129 mM citrate were longer than those collected in 105 mM both for normals and patients on OAT, but the ratios (patient-to-normal clotting times) for the two citrate concentrations were significantly different in many instances, implying that the International Sensitivity Index (ISI) is also different. ISIs for calibrations with plasmas collected in 105 mM were greater (up to 10%) than those with plasmas collected in 129 mM citrate. When PT ratios were transformed into INR using crossover ISIs (i.e., plasmas collected in 105 mM and ISI determined with plasmas collected in 129 mM citrate, or vice versa) we found that an INR of 4.5 could be up to 20% apart from the value that would have been obtained if the appropriate ISI was used. Moreover, if the ISI determined with the manual technique was used to convert PTs obtained with a particular instrument into INR, the effect of citrate concentration was even greater (INR difference up to 64%). Should these observations be valid for other systems, they might provide additional explanations for the frequent reports which document discrepancies in the INR determined with different systems to which incorrect ISI might have been applied. World-wide consensus on a single citrate concentration to collect patients’ as well as lyophilized plasmas to be used in External Quality Assessment Schemes and for local system calibration is therefore urgently needed.

^* This study was carried out within the frame of activity of the CISMEL, Hemostasis Subcommittee (Comitato Italiano per la Standardizzazione dei Metodi in Ematologia e Laboratorio)

• References

• 1 WHO Expert Committee on Biological Standardisation.. Thirty-third Report. Technical Report Series 687. WHO; Geneva: 1983
• 2 Kitchen S, Walker ID, Woods TAL, Preston FE. Thromboplastin related differences in the determination of International Normalized Ratio: a cause for concern?. Thromb Haemost 1994; 72: 426-9.
• 3 Holland LJ, Lawrie AS, Hunt BJ. Evidence of discrepant commercial ISI assignment. Blood Coag Fibr 1992; 3: 493-4.
• 4 van den Besselaar AMHP, Lewis SM, Mannucci PM, Poller L. Status of present and candidate international reference preparations (IRP) of thromboplastin for the prothrombin time. Thromb Haemost 1993; 69: 85.
• 5 Poller L, Hougthon D, Carroll J. The reliability of the mean normal prothrombin time of fresh plasmas and of the normal value from a lyophilized “normal” plasma in prothrombin time determination. Brit J Haematol 1994; 88: 866-73.
• 6 Poggio M, van den Besselaar AMHP, van der Velde EA, Bertina RM. The effect of some instruments for prothrombin time testing on the International Sensitivity Index (ISI) of two rabbit tissue thromboplastin reagents. Thromb Haemost 1989; 62: 868-74.
• 7 Chantarangkul V, Tripodi A, Mannucci PM. The effect of instrumentation on thromboplastin calibration. Thromb Haemost 1992; 67: 588-9.
• 8 Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K. The value of plasma calibrants in correcting coagulometer effects on International Normalized Ratio. Am J Clin Path 1995; 103: 358-65.
• 9 Ingram GIC, Hills M. The Prothrombin Time Test: Effect of varying citrate concentration. Thromb Haemost 1976; 36: 230-36.
• 10 Hermans J, van den Besselaar AMHP, Loeliger EA, van der Velde EA. A collaborative calibration study of reference materials for thromboplastins. Thromb Haemost 1983; 50: 712-7.
• 11 van den Besselaar AMHP. Multicenter study of replacement of the international reference preparation for thromboplastin, rabbit, plain. Thromb Haemost 1993; 70: 794-9.
• 12 Tripodi A, Chantarangkul V, Negri B, Clerici M, Mannucci PM. International collaborative study for the calibration of a proposed reference preparation for thromboplastin, human recombinant, plain. Thromb Haemost. 1998 In press.
• 13 Duncan EM, Casey CR, Duncan BM, Lloyd JV. Effect of concentration of trisodium citrate anticoagulant on calculation of the International Normalised Ratio and the International Sensitivity Index of thromboplastin. Thromb Haemost 1994; 72: 84-8.
• 14 Thomson JM, Darby KV, Poller L. Calibration of BCT/441, the ICSH Reference Preparation for Thromboplastin. Thromb Haemost 1986; 55: 379-82.
• 15 van der Velde EA. Orthogonal regression lines. In: Thromboplastin Calibration and Oral Anticoagulant Control. van den Besselaar AMHP, Gralnick HR, Lewis SM. eds. Boston: Martinus Nijhoff Publishers; 1984. pp 25-39.
• 16 Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs. 3. 8 % sodium citrate concentration on routine coagulation testing. Am J Clin Pathol 1997; 107: 105-10.
• 17 Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K. The value of plasma calibrants in correcting coagulometer effects on International Normalized Ratios. Am J Clin Path 1995; 103: 358-65.
• 18 van den Besselaar AMHP. Comparison of lyophilized plasmas with fresh plasmas for calibration of thromboplastin reagents in oral anticoagulant control. Brit J Haemat 1996; 93: 437-44.
• 19 Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy. In: WHO Expert Committee on Biological Standardization. Forty-eighth report. WHO; Geneva: In press.